Bosutinib indications

Bosutinib/Bosutinib (Bosutinib) is a targeted therapy drug mainly used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). CML is a hematological malignant tumor. Bosutinib controls the proliferation of leukemia cells by inhibiting the BCR-ABL fusion protein. As a second-generation tyrosine kinase inhibitor (TKI), bosutinib has certain advantages over other TKI drugs, especially in patients who are resistant to other treatment options.

The main indications for bosutinib are adult patients and pediatric patients aged 1 year and above. First, bosutinib provides an effective treatment option for adults with newly diagnosed chronic-phase Ph+ CML. Traditional treatment methods such as imatinib and other first-line TKI drugs may cause drug resistance or side effect intolerance in some patients, while bosutinib can be used as an alternative treatment drug to effectively control the disease and delay disease progression.

In addition to newly diagnosed patients, bosutinib is also indicated for patients with Ph+ CML in the chronic, accelerated or blast phaseThese patients often have developed resistance or intolerance to previous treatments. Bosutinib overcomes these drug resistance problems through different mechanisms, thus providing patients with more choices during treatment. Especially when the patient's condition is not under control, bosutinib has demonstrated obvious efficacy.

The indications of Bosutinib are not limited to adult patients. Bosutinib also provides an effective treatment option for pediatric patients 1 year old and above, especially those with newly diagnosed chronic phase Ph+ CML or those who are resistant to previous treatments. Treatment of pediatric patients requires dose adjustment based on body surface area, so individualization of treatment regimens is important.

Reference materials:https://go.drugbank.com/drugs/DB06616